• Home (current)
  • La Società
    Chi siamo Soci collettivi Collaborazioni tecniche Bilancio societario
  • Sezioni Regionali
  • Convegni e Formazione
    Eventi SINU Altri eventi Eventi patrocinati
  • Newsletters
  • Cerca
  • Come iscriversi
  • Area Soci:
  • Registrati
  • Login
  • English version
  • Passa al contenuto principale

SINU

Società Italiana di Nutrizione Umana

EFSA – Rischi per la salute umana associati alla presenza di PFAS negli alimenti

The European Commission asked EFSA for a scientific evaluation on the risks to human health related to the presence of perfluoroalkyl substances (PFASs) in food. Based on several similar effects in animals, toxicokinetics and observed concentrations in human blood, the CONTAM Panel decided to perform the assessment for the sum of four PFASs: PFOA, PFNA, PFHxS and PFOS. These made up half of the lower bound (LB) exposure to those PFASs with available occurrence data, the remaining contribution being primarily from PFASs with short half‐lives. Equal potencies were assumed for the four PFASs included in the assessment. The mean LB exposure in adolescents and adult age groups ranged from 3 to 22, the 95th percentile from 9 to 70 ng/kg body weight (bw) per week. Toddlers and ‘other children’ showed a twofold higher exposure. Upper bound exposure was 4‐ to 49‐fold higher than LB levels, but the latter were considered more reliable. ‘Fish meat’, ‘Fruit and fruit products’ and ‘Eggs and egg products’ contributed most to the exposure. Based on available studies in animals and humans, effects on the immune system were considered the most critical for the risk assessment. From a human study, a lowest BMDL10 of 17.5 ng/mL for the sum of the four PFASs in serum was identified for 1‐year‐old children. Using PBPK modelling, this serum level of 17.5 ng/mL in children was estimated to correspond to long‐term maternal exposure of 0.63 ng/kg bw per day. Since accumulation over time is important, a tolerable weekly intake (TWI) of 4.4 ng/kg bw per week was established. This TWI also protects against other potential adverse effects observed in humans. Based on the estimated LB exposure, but also reported serum levels, the CONTAM Panel concluded that parts of the European population exceed this TWI, which is of concern.

Consulta il documento


HOME

LARN IV revisione
NMCD
Meno sale più salute
Come iscriversi
Questionari
Il Punto su…
Congresso SINU 2019
Documenti SINU

LA SOCIETA'

Chi siamo
Soci collettivi
Collaborazioni tecniche
Biancio societario

FORMAZIONE

Eventi SINU
Altri eventi
Eventi patrocinati

NEWS

In evidenza
News recenti

CONTATTI

Sezioni regionali
Gruppi di lavoro
Privacy policy

SEGRETERIA SINU

c/o BioMedia srl
via Libero Temolo 4
20126 Milano
02 45498282
02 45498199
info@sinu.it

Copyright © 2019 SINU - Tutti i diritti riservati.


Un progetto realizzato da: BioMedia srl.

Recupera password

Presto Disponibile